# Advances in Digital Therapeutics and HoneyNaps AI Enhance Clinical Trial Efficiency

- Link: https://www.thailand-business-news.com/pr-news/advances-in-digital-therapeutics-and-honeynaps-ai-enhance-clinical-trial-efficiency
- Published: 2026-10-01T18:00:00+07:00
- Author: PR Newswire

◦ _ Supporting pharmaceutical, medical device, wellness, and research organizations
   in obtaining standardized sleep data_
 ◦ _ Expanding the use of SOMNUM scoring technology to provide clinical analysis
   services tailored to each customer’s research objectives_
 ◦ _ AI Technologies Supporting Global Clinical Trials in Drug Development_

BOSTON, Oct. 1, 2026 /PRNewswire/ — More pharmaceutical companies and research organizations
are turning to HoneyNaps, an AI-based sleep health technology company, for objective
analysis and validation of sleep data. Demand spans clinical trials of sleep medications,
evaluations of wellness sleep devices and home-care products, and studies involving
positive airway pressure (PAP) therapy and cardiovascular disease. In response, 
HoneyNaps is broadening the scope of its clinical analysis services.

[⌊SOMNUM Clinical Trials⌉⌊SOMNUM Clinical Trials⌉[
SOMNUM Clinical Trials

HoneyNaps has completed registration as a clinical research organization (CRO) with
the Korea National Enterprise for Clinical Trials (KoNECT). It combines AI-powered
sleep analysis technology with experience supporting clinical trials involving more
than 10,000 participants and the capabilities to operate multicenter, multidisciplinary
studies. Its clinical sleep data analysis services quantify key physiological measures
obtained through polysomnography (PSG), including sleep stages, respiratory events,
and arousals, and support the analysis of clinical endpoints aligned with each study’s
objectives.

Although research objectives vary across sectors, pharmaceutical companies, device
developers, and research organizations share a need for objective, consistent sleep
data. Evaluating treatment response or device performance requires sleep metrics
to be analyzed against consistent criteria while minimizing variability between 
institutions and scorers. The need to establish reliable and reproducible data is
driving growing interest in HoneyNaps’ sleep analysis technology.

As demand for sleep data analysis and validation grows across sectors, HoneyNaps
is extending its business beyond sleep scoring with its SOMNUM platform into clinical
analysis services for the pharmaceutical, wellness, and medical device industries.
Data quantifying sleep architecture and continuity, respiratory patterns, and oxygen
saturation changes may also serve as foundational evidence for future digital biomarker
development.

Taekyoung (Sean) Ha, PhD, President of HoneyNaps USA, said, "Pharmaceutical companies,
device developers, and research organizations pursue different research objectives,
but they share a need for objective and consistent sleep data. As more customers
across these sectors turn to HoneyNaps to obtain such data, we are expanding both
the applications of our existing scoring technology and the business areas that 
contribute to revenue." 

He added, "We will continue to support the generation of clinical evidence through
endpoints suited to each study and standardized analysis criteria, while diversifying
our revenue base."

**For further information, please contact:HoneyNaps USA, Inc.
Christine Kwon / Managing
DirectorEmail: [sleep@honeynaps.com](https://www.thailand-business-news.com/pr-news/sleep@honeynaps.com)
Address: 14^(th) Floor, One Broadway, Cambridge, MA 02142, USAWebsite: [www.honeynaps.com](http://www.honeynaps.com/)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Advances in Digital Therapeutics and HoneyNaps AI Enhance Clinical Trial Efficiency ](http://www.prnasia.com/story/archive/5061633_CN61633_0?rand=184833)